Welcome to our dedicated page for Supernus Pharma SEC filings (Ticker: SUPN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Supernus Pharmaceuticals, Inc. (SUPN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Supernus is a biopharmaceutical company focused on developing and commercializing products for central nervous system (CNS) diseases, and its filings offer detailed insight into its commercial portfolio, collaborations, and pipeline.
Supernus’s current reports on Form 8-K cover a range of material events. These include announcements of quarterly financial results, where the company reports total revenues, net product sales for CNS therapies such as Qelbree, GOCOVRI, APOKYN, Trokendi XR, Oxtellar XR, ONAPGO, and other products, as well as royalty, licensing and other revenues and collaboration revenue from ZURZUVAE. Filings also describe non-GAAP measures like adjusted operating earnings and revenues excluding certain legacy products.
Other 8-K filings document corporate transactions, notably the acquisition of Sage Therapeutics, Inc. Supernus details the merger structure, consideration, contingent value rights (CVRs) tied to ZURZUVAE milestones, and the integration of Sage as a wholly owned subsidiary. These filings also outline the collaboration economics with Biogen Inc. related to ZURZUVAE, an oral treatment for postpartum depression.
Additional disclosures address operational updates, such as supply constraints for ONAPGO due to stronger than expected demand and the company’s decision to prioritize existing patients while working to rebuild inventory. Filings also announce upcoming earnings release dates and conference calls, reinforcing the company’s regular reporting cadence.
On Stock Titan, investors can use AI-powered tools to read concise summaries of Supernus’s 8-Ks and other SEC documents, quickly understand key points about CNS product performance, collaboration revenue, acquisitions, and pipeline developments, and identify items such as contingent value rights or other material agreements without manually parsing lengthy filings.
Jack A. Khattar, President and CEO and a director of Supernus Pharmaceuticals, Inc. (SUPN), reported transactions on 10/01/2025 showing the acquisition and sale of company common stock. He acquired 53,785 shares pursuant to an employee stock option with an exercise price of $25.30 and also sold 40,173 shares at a weighted average price of $48.07. The acquisition was made under a 10b5-1 trading plan adopted November 14, 2024, and the sale occurred in multiple transactions at prices ranging from $48.00 to $48.25.
After these transactions Mr. Khattar directly beneficially owns 1,160,870 shares and indirectly (through the KBT Trust) holds 1,005,600 shares, for a combined reported interest disclosed on the form. The exercised option vests in four equal installments beginning on 02/24/2018 and expires on 02/24/2027.
Insider notice to sell 40,173 common shares of Supernus Pharmaceuticals (SUPN) is reported under Form 144. The sale is scheduled for 10/01/2025 through Morgan Stanley Smith Barney and the aggregate market value of the proposed sale is $1,919,867.67. The shares were acquired on 10/01/2025 by exercise of stock options and payment was made in cash on the same date. The filing shows 56,073,088 shares outstanding for the class referenced. The filing also lists multiple prior 10b5-1 sales by the same account over the past three months totaling 304,123 shares.
Jack A. Khattar, President, CEO and director of Supernus Pharmaceuticals (SUPN), reported transactions on 09/30/2025. He exercised an employee stock option to acquire 11,510 shares at an exercise price of $25.30 per share under a plan adopted 02/24/2018, and sold 8,588 shares in multiple trades at a weighted average price of $48.25 (individual sale prices ranged $48.00–$48.44). After these transactions Mr. Khattar beneficially owned 1,147,258 shares directly and an additional 1,005,600 shares indirectly through the KBT Trust. The option activity leaves 137,302 option shares outstanding held directly.
Form 144 filing for SUPN reports a proposed sale of 8,588 shares of common stock to be executed through Morgan Stanley Smith Barney LLC on 09/30/2025 on NASDAQ with an aggregate market value of $408,788.80. The filing states these shares were acquired and will be paid for on 09/30/2025 by exercise of stock options from the issuer. The document also lists multiple recent Rule 10b5-1 sales by Jack A. Khattar totaling numerous transactions in August and September 2025, including sales on 09/29/2025, 09/23/2025, 09/22/2025, and earlier dates, each showing amounts and gross proceeds. The filing shows total shares outstanding of 56,073,088, providing context for the size of the proposed sale within the company's capitalization.
Jack A. Khattar, President & CEO and a director of Supernus Pharmaceuticals, Inc. (SUPN), reported option-related and open-market transactions on 09/29/2025. He acquired 13,688 shares by exercising employee stock options at an exercise price of $25.30 and, on the same date, sold 10,235 shares in transactions at a weighted average price of $48.02 (sales ranged from $48.00 to $48.14). After these transactions he beneficially owns 1,144,336 shares directly and 1,005,600 shares indirectly through the KBT Trust; he also holds 148,812 option shares underlying employee stock options. The exercise was recorded as part of an option vesting schedule; the sales were made pursuant to a 10b5-1 trading plan adopted November 14, 2024. The form was signed by an attorney-in-fact on 09/30/2025.
Form 144 notice for SUPN (Supernus Pharmaceuticals, Inc.) shows an insider sale filing for common stock scheduled with Morgan Stanley Smith Barney. The filer reports proposing to sell 10,235 shares on 09/29/2025 with an aggregate market value of $481,352.05. The shares were acquired the same day (09/29/2025) via exercise of stock options and payment was in cash. The filing lists total shares outstanding of 56,073,088, which places the proposed sale at a very small fraction of outstanding stock. The notice also discloses multiple Rule 10b5-1 sales by Jack A. Khattar during August–September 2025 totaling 285,300 shares for combined gross proceeds of approximately $12,588,665.79. The filer certifies no undisclosed material adverse information and references Rule 10b5-1 plan representations.
Jonathan Rubin, SVP and Chief Medical Officer of Supernus Pharmaceuticals (SUPN), reported transactions on 09/25/2025 relating to Performance Share Units (PSUs). 1,875 shares of common stock were acquired on settlement of PSUs at $0 (transaction code M) and 840 shares were withheld to satisfy tax withholding at a price of $46.21 (transaction code F).
Following these transactions, Mr. Rubin beneficially owned 11,015 shares (direct ownership). The filing notes the PSUs were granted on February 22, 2024, with certain awards vesting upon achievement of individual performance objectives established June 24, 2024.
Jack A. Khattar, President, CEO and a director of Supernus Pharmaceuticals (SUPN), reported transactions on 09/23/2025. He acquired 47,940 shares by exercising employee stock options with an exercise price of $12.98 (options vested in installments beginning 03/01/2017; expiration 03/01/2026). On the same date he sold 29,513 shares in multiple transactions at a weighted average price of $47.23. The acquisition was made pursuant to a 10b5-1 trading plan adopted 11/14/2024. Following these transactions his direct beneficial ownership is reported as 1,140,883 shares, and he also holds 1,005,600 shares indirectly through the KBT Trust. The form was signed by an attorney-in-fact on 09/24/2025.
Jack A. Khattar, President, CEO and a director of Supernus Pharmaceuticals (SUPN), reported transactions on 09/22/2025. He exercised 27,060 employee stock options with an exercise price of $12.98 (resulting from options granted earlier) and acquired 27,060 shares. On the same date he sold 16,587 shares at a weighted-average price of $47.02. Following these transactions the filing shows 1,122,456 shares beneficially owned directly and 1,005,600 shares indirectly through the KBT Trust. The exercise and acquisition were reported as made pursuant to a 10b5-1 trading plan adopted November 14, 2024. The Form 4 was signed by an attorney-in-fact on 09/23/2025.
Form 144 filing for Supernus Pharmaceuticals, Inc. (SUPN) reports a proposed sale of 29,513 shares of common stock through Morgan Stanley Smith Barney on 09/23/2025 to be executed on the NASDAQ. The shares were acquired and paid for on 09/23/2025 by exercise of stock options, with payment in cash. The filing also lists multiple Rule 10b5-1 sales by Jack A. Khattar over August–September 2025, showing several transactions and gross proceeds. The notice includes the seller's representation regarding absence of undisclosed material information.